1. Home
  2. MLYS vs CSWC Comparison

MLYS vs CSWC Comparison

Compare MLYS & CSWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$20.29

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

SELL

Current Price

$23.12

Market Cap

1.6B

ML Signal

SELL

Company Overview

Basic Information
Metric
MLYS
CSWC
Founded
2019
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Textiles
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
MLYS
CSWC
Price
$20.29
$23.12
Analyst Decision
Strong Buy
Buy
Analyst Count
11
7
Target Price
★ $46.33
$25.08
AVG Volume (30 Days)
★ 1.4M
506.1K
Earning Date
11-09-2026
11-02-2026
Dividend Yield
N/A
★ 10.89%
EPS Growth
★ 37.43
29.25
EPS
N/A
★ 0.39
Revenue
N/A
★ $10,835,000.00
Revenue This Year
N/A
$14.86
Revenue Next Year
N/A
$13.58
P/E Ratio
★ N/A
$60.41
Revenue Growth
N/A
★ 16.08
52 Week Low
$20.41
$19.91
52 Week High
$47.65
$25.75

Technical Indicators

Market Signals
Indicator
MLYS
CSWC
Relative Strength Index (RSI) 32.24 39.39
Support Level N/A $22.76
Resistance Level $31.19 $23.86
Average True Range (ATR) 1.27 0.32
MACD -0.29 0.03
Stochastic Oscillator 4.06 28.56

Price Performance

Historical Comparison
MLYS
CSWC

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.

Share on Social Networks: